Lilly Pays Nearly $1bn To Regain Migraine Candidate It Once Sold For $1m
In acquiring biotech CoLucid and its Phase III acute migraine candidate lasmiditan for $960m, Lilly gets back an asset it discovered and out-licensed more than a decade ago. The pharma hopes to pair the 5-HT1F agonist with galcanezumab to create a two-drug migraine franchise.
You may also be interested in...
Lilly Expands Migraine Franchise With Reyvow Approval
Reyvow gives Lilly a second MOA in migraine, following the anti-CGRP biologic Emgality, and adds an acute therapy to the preventive agent approved in 2018.
Lilly's Lasmiditan NDA Review Could Hinge On US FDA's Migraine Guidance
Potential first-in-class on-demand oral migraine treatment would complement new prevention products from Lilly, Amgen and Teva.
Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?
Galcanezumab was able to reduce episodic cluster headaches compared to placebo, but missed statistical significance for chronic cluster headaches. Amgen’s Aimovig still is first in line to reach the market in the anti-CGRP class.